MedPath

Goserelin

Generic Name
Goserelin
Brand Names
Zoladex
Drug Type
Small Molecule
Chemical Formula
C59H84N18O14
CAS Number
65807-02-5
Unique Ingredient Identifier
0F65R8P09N
Background

Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.

Indication

Goserelin is indicated for:

Associated Conditions
Abnormal Uterine Bleeding, Advanced Breast Cancer, Endometriosis, Advanced carcinoma of the prostate, Stage T2b carcinoma of the prostate, Stage T4 carcinoma of the prostate
Associated Therapies
Palliative Treatment
Clinical Trials
Related News

Bipolar Androgen-based Therapy for Prostate Cancer (BAT)

Phase 2
Completed
Conditions
Recurrent Prostate Cancer
Interventions
Drug: Testosterone cypionate
Drug: Goserelin
Drug: Leuprolide
First Posted Date
2012-12-17
Last Posted Date
2016-12-05
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Target Recruit Count
33
Registration Number
NCT01750398
Locations
🇺🇸

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Phase 3
Completed
Conditions
Prostate Cancer
Interventions
Drug: Degarelix
Drug: Goserelin
First Posted Date
2012-12-06
Last Posted Date
2015-06-23
Lead Sponsor
Ferring Pharmaceuticals
Target Recruit Count
285
Registration Number
NCT01744366
Locations
🇨🇳

Affiliated Southwest Hospital of 3rd Military Medical University of People's Liberation Army, Chongqing, Chongqing, China

🇨🇳

2nd.Affiliated Hospital of Xi'an Jiaotong University College of Medicine, Xi'an, Shanxi, China

🇨🇳

Cancer Institute & Hospital. Chinese Academy of Medical Sciences, Beijing, Beijing, China

and more 26 locations

Study of the Efficacy of Dienogest in the Treatment of Uterine Leiomyomas When Compared to Desogestrel and Goserelin

Phase 4
Terminated
Conditions
Uterine Leiomyoma
Interventions
Drug: Dienogest
Drug: Goserelin
Drug: Desogestrel
First Posted Date
2012-11-30
Last Posted Date
2020-08-13
Lead Sponsor
University of Sao Paulo
Target Recruit Count
14
Registration Number
NCT01738724

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

Phase 2
Active, not recruiting
Conditions
Breast Neoplasms
Interventions
Drug: PD0332991
Drug: Anastrozole
Drug: Goserelin
Procedure: Surgery (standard of care)
Procedure: Tumor biopsy
First Posted Date
2012-11-08
Last Posted Date
2024-12-03
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
84
Registration Number
NCT01723774
Locations
🇺🇸

Mayo Clinic - Scottsdale, Scottsdale, Arizona, United States

🇺🇸

Mayo Clinic - Rochester, Rochester, Minnesota, United States

🇺🇸

University of Alabama, Birmingham, Alabama, United States

and more 1 locations

Simultaneous Versus Sequential Use of Adjuvant Chemotherapy and GnRHa in Treating ER+,Premenopausal Breast Cancer

Phase 3
Completed
Conditions
Breast Cancer
Interventions
Drug: Zoladex
First Posted Date
2012-10-24
Last Posted Date
2017-08-25
Lead Sponsor
Fudan University
Target Recruit Count
216
Registration Number
NCT01712893
Locations
🇨🇳

FUSCC, Shanghai, Shanghai, China

The Influence of Adjuvant Medical Treatment of Peritoneal Endometriosis on the Outcome of IVF. A Prospective Randomized Analysis.

Phase 4
Completed
Conditions
Endometriosis
Infertility
Interventions
Drug: Zoladex
First Posted Date
2012-09-11
Last Posted Date
2015-03-20
Lead Sponsor
AZ Jan Palfijn Gent
Target Recruit Count
120
Registration Number
NCT01682642
Locations
🇧🇪

AZ Jan Palfijn, Gent, Oost-vlaanderen, Belgium

Tecemotide (L-BLP25) in Prostate Cancer

Phase 2
Completed
Conditions
Prostate Cancer
Interventions
Radiation: Radiation therapy
Drug: Goserelin
Drug: Cyclophosphamide
Drug: Tecemotide (L-BLP25)
First Posted Date
2011-12-21
Last Posted Date
2018-03-09
Lead Sponsor
EMD Serono
Target Recruit Count
28
Registration Number
NCT01496131
Locations
🇺🇸

Please Contact US Medical Information, Rockland, Massachusetts, United States

Ipilimumab + Androgen Depravation Therapy in Prostate Cancer

Phase 2
Terminated
Conditions
Prostate Cancer
Interventions
Drug: Ipilimumab
Drug: Leuprolide
Drug: Goserelin
Drug: Degarelix
First Posted Date
2011-06-21
Last Posted Date
2023-09-29
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
30
Registration Number
NCT01377389
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women

Phase 2
Conditions
Metastatic Breast Cancer
Estrogen Receptor Positive Tumor
Breast Cancer Nos Premenopausal
Interventions
Drug: Fulvestrant plus Goserelin
Drug: Anastrozole plus Goserelin
Drug: Goserelin
First Posted Date
2010-12-24
Last Posted Date
2017-05-01
Lead Sponsor
Samsung Medical Center
Target Recruit Count
147
Registration Number
NCT01266213
Locations
🇰🇷

Samsung Medical Center, Seoul, Korea, Republic of

International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer

Phase 2
Completed
Conditions
Prostate Cancer
Interventions
Drug: Ozarelix
Drug: Goserelin
First Posted Date
2010-12-03
Last Posted Date
2021-10-05
Lead Sponsor
Spectrum Pharmaceuticals, Inc
Target Recruit Count
203
Registration Number
NCT01252693
Locations
🇺🇸

Urology Clinics of North Texas, Dallas, Texas, United States

🇺🇸

The Urology Center of Colorado, Denver, Colorado, United States

🇺🇸

Urology San Antonio Research, San Antonio, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy